Predicting Chemotherapy Response with Affected person-Derived Gastric Most cancers Organoids

This webinar will be hosted live and available on-demand.

Tuesday, April 7th, 2026
11:00 AM – 12:00 PM ET

Treating gastric cancer is difficult due to tumor heterogeneity. However, organoids are proven research tools capable of simulating the 3D structures, cellular interactions, and tumor heterogeneity associated with cancer. Researchers at the University of Liverpool established gastric organoid biobanks from normal tissue and gastric adenocarcinoma samples, and used these to examine responses to neoadjuvant fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in vitro. 

In this webinar, brought to you by Axion Biosystems, Mushfique Alam will discuss how live-cell imaging can generate rapid, quantitative readouts from patient-derived gastric cancer organoids.

Topics to be covered

• Understand how patient-derived gastric cancer organoids model tumor heterogeneity
• Learn how the Omni live-cell imaging platform generates quantitative and longitudinal readouts of organoid responses to FLOT chemotherapy in vitro
• Explore how functional drug profiling with organoid biobanks can support precision oncology approaches

Mushfique Alam Surgical Registrar/Senior Resident  University Hospitals of Liverpool Group Clinical Research Fellow University of Liverpool